Major Breakthrough For Antares Pharma Inc (NASDAQ:ATRS)

Posted by Ryan Mandell October 16, 2013 0 Comment 1504 views

Otrexup, Antares Pharma Inc (NASDAQ:ATRS)’s injectible drug that is used in the treatment of difficult to treat arthritis and psoriasis cases, received the U.S. Food and Drug Administration nod. It is an alternative to pills. Paul Wotton, the company’s President and CEO said that this approval is a very strategic milestone for Antares Pharma Inc (NASDAQ:ATRS) and the Vibex Medi-Jet proprietary technology. The company has numerous other products that are in developmental stages, and which use this same technology. Otrexup is expected to be commercially launched in early 2014.

A first of its kind

Antares Pharma Inc (NASDAQ:ATRS) has said that this is the very first Methotrexate, patient-administrable drug that has received FDA approval. Patients can use this once a week and it has a disposable auto-injector. This drug is prescribed for patients suffering from severe active-rheumatoid arthritis, children suffering from active polyarticular juvenile-idiopathic arthritis as well as patients suffering from psoriasis, the skin disease. Otrexup offers an ideal alternative when patients have not responded adequately to methotrexate pills or for those who have tolerability-issues with any oral drug.

Tuesday’s trading

In Tuesday’s trading, Antares Pharma Inc (NASDAQ:ATRS) dropped by 6.93%. The opening price of the shares was $4.67, which climbed to an intraday high of $4.69 and dipped to a close of $4.36. Approximately 5.20 million shares were traded on Tuesday while an average volume of 2.01 million shares were traded over a 30 day period. The 52-week low of Antares Pharma Inc (NASDAQ:ATRS) shares is $3.35 and its 52-week high is $5.15. The company has a market capitalization of $555.05 million.

About the company

Antares Pharma Inc (NASDAQ:ATRS) is a pharmaceuticals company. It is focused on various self-injection pharmaceutical products & technologies as well as topical gel-based products. Antares Pharma Inc (NASDAQ:ATRS)’s subcutaneous and intramuscular-injection technology platforms are Vibex disposable-pressure-assisted auto injectors, Vision reusable-needle-free injectors, and disposable multi-use-pen injectors.

About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment